問卷

TPIDB > Search Result

Search Result

篩選

List

29Cases

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Subcutaneous injection Injection Injection Injection Injection

Participate Sites
7Sites

Recruiting7Sites

2020-09-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-03-01 - 2028-06-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-12-14 - 2024-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-08-31 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2025-06-18 - 2027-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-10-31 - 2029-02-28

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2026-01-27 - 2030-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3